How many billions is enough? Prioritizing profits over patients with cystic fibrosis
Pediatric Pulmonology · 2023
DOI: 10.1002/ppul.26335 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Pulmonology, 2023. Verfasst von Meghan E McGarry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Pulmonary Medicine, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NIMHD NIH HHS.
Abstract (Originalsprache)
CFTR modulators have drastically improved outcomes for many people with cystic fibrosis (CF), including improved lung function and increased life expectancy by targeting the defective CFTR protein 1,2 .As a result, many more people with CF are now fulfilling key life milestones, including pursuing education, careers, and parenthood 3 .We applaud the research and development efforts of Vertex Pharmaceuticals, the sole manufacturer of CFTR modulators.Vertex has been heralded as a shining star of pharmaceutical companies for personalized medicine and rare disease and has a stated commitment to the CF community.However, we are appalled at how Vertex is achieving financial success on the backs of vulnerable populations.Only a small percentage of people with CF worldwide have access to these disease-altering CFTR modulators due to Vertex not allowing the development of generic forms or lowering pricing for lower-income or middle-income countries (LMICs), as done by other pharmaceutical companies for HIV, Hepatitis C, and Covid-19 medications 4 .Due to Vertex's refusal to assist LMICs and Vertex holding the patent for elexacaftor/tezacaftor/ivacaftor until 2037, LMICs will not have generic ETI available for 14 more years.An entire generation of people with CF in LMICs may therefore miss out on the profound benefit Conflict of Interest: Dr. Sawicki
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pediatric Pulmonary Medicine, University of California San Francisco, San Francisco, California, USA.
- Department of Pediatrics, Division of Pulmonary Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Department of Pediatrics, Division of Pediatric Pulmonology, Geisel School of Medicine at Dartmouth College, Hanover, New Hampshire, USA.
- Department of Pediatrics, Division of Pulmonary Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pharmacotherapy, University of Utah, Salt Lake City, Utah, USA.
ORCID-Profile: Meghan E McGarry, Theresa A Laguna, Gregory S Sawicki, Jeffery T Zobell
Förderung
- NHLBI NIH HHS
- NIMHD NIH HHS
Zitieren
APA
McGarry, M. E., Gibb, E. R., Laguna, T. A., O'Sullivan, B. P., Sawicki, G. S., & Zobell, J. T. (2023). How many billions is enough? Prioritizing profits over patients with cystic fibrosis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26335
Vancouver
McGarry ME, Gibb ER, Laguna TA, O'Sullivan BP, Sawicki GS, Zobell JT. How many billions is enough? Prioritizing profits over patients with cystic fibrosis. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26335
BibTeX
@article{McGarry2023,
author = {McGarry, Meghan E and Gibb, Elizabeth R and Laguna, Theresa A and O'Sullivan, Brian P and Sawicki, Gregory S and Zobell, Jeffery T},
title = {How many billions is enough? Prioritizing profits over patients with cystic fibrosis},
journal = {Pediatric Pulmonology},
year = {2023},
doi = {10.1002/ppul.26335}
}
EUVIMED